Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
SAN DIEGO — Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms.
Article content
Through this collaboration, LabPMM (Invivoscribe's global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to support CERo's clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML.
Article content
AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis. 1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chimeric antigen receptor T-cells) and Chimeric Engulfment Receptor T-cells ('CER-T') therapies, which involve engineering a patient's own T-cells to recognize and attack cancer cells, have shown promise in other hematologic malignancies and are now being explored for AML. However, because these therapies are manufactured from patient-derived cells, it's critical to confirm that leukemic blasts are not inadvertently included in the final therapeutic product – underscoring the need for sensitive, validated assays like those offered by Invivoscribe and its global accredited regional laboratories, LabPMM.
Article content
LabPMM's CAP/CLIA-Validated AML MRD MFC assay, which was designed to quantify residual leukemic cells in patients undergoing treatment, was customized to meet two critical needs in CERo's drug development program: (1) assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and (2) evaluating therapeutic response to CER-1236 during the trial.
Article content
Kristen Pierce, Ph.D., CERo Chief Development Officer, commented, 'Invivoscribe has played an integral role in the execution of this clinical trial. Its technology and expertise have facilitated our advancement into the clinic by helping to ensure the purity of our investigational product, and now we are reaping the benefits of our collaboration as the trial is underway and we seek to assess therapeutic response.'
Article content
This collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for the treatment of AML 2. The designation highlights the growing urgency of integrated diagnostic support in the advancement of personalized immunotherapies and reflects Invivoscribe's commitment to driving innovation and standardization across the oncology treatment landscape – now helping bring immunotherapies to patients faster.
Article content
For more information about LabPMM's flow cytometry and molecular testing services, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.
Article content
About Invivoscribe Inc.
Article content
Invivoscribe ® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics ®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM ®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
Article content
About CERo Therapeutics Holdings, Inc.
Article content
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Dr. Yorell Manon Matos Launches National Grant to Address Economic Challenges in Healthcare
New Opportunity for Undergraduate Students Pursuing Careers in Medicine and Healthcare Fields SIOUX FALLS, S.D. - The Dr. Yorell Manon Matos Grant for Healthcare Students is now officially accepting applications for its 2025 cycle, offering financial support to undergraduate students committed to transforming the future of healthcare. This national initiative is designed to recognize and support high-achieving individuals pursuing degrees in medicine, nursing, public health, and other healthcare-related fields. Founded by Dr. Yorell Manon Matos, a respected hand and microsurgeon based in South Dakota, this grant initiative reflects his dedication to developing the next generation of medical professionals. With a distinguished academic and professional background, including training at Dartmouth Medical School, Tufts University, and the Christine M. Kleinert Institute Dr. Yorell Manon Matos brings years of clinical excellence and educational leadership to this initiative. The Dr. Yorell Manon Matos Grant for Healthcare Students is open to undergraduate students enrolled at accredited universities or colleges across the United States. Eligible applicants must be pursuing a degree in healthcare or a closely related field and must demonstrate academic excellence with a minimum GPA of 3.0. Additionally, applicants should show a clear commitment to improving healthcare systems through innovative thinking, policy awareness, and a dedication to service. At the heart of the application process is a required essay responding to the prompt: 'Discuss the economic challenges in healthcare today. How do you think innovations and policies could improve both affordability and quality of care for patients?' The essay should be between 1,000 and 1,500 words and must reflect critical analysis, originality, and a clear understanding of the economic complexities within the healthcare system. Applicants are also required to submit a brief cover letter alongside their essay. Submissions must be sent via email to apply@ by August 15, 2025. The winning applicant will be announced on September 15, 2025, and will receive a one-time financial award to support their academic journey in healthcare. Through this grant, Dr. Yorell Manon Matos seeks to encourage thoughtful engagement with pressing healthcare issues and to support students who are determined to make a lasting impact in their respective fields. His ongoing clinical work at the Center for Neuroscience, Orthopaedics, and Spine in South Dakota continues to inspire his commitment to mentorship, education, and patient care. This initiative builds on Dr. Yorell Manon Matos' career-long dedication to excellence in healthcare delivery and academic leadership. By launching the grant, Dr. Yorell Manon Matos aims to create a meaningful opportunity for emerging healthcare professionals to deepen their understanding of healthcare economics while receiving support for their academic endeavors. The Dr. Yorell Manon Matos Grant for Healthcare Students reflects a broader mission to address systemic healthcare challenges by investing in the potential of students who aspire to lead, heal, and innovate. With healthcare continuing to evolve rapidly, programs like this serve as a critical support system for young professionals preparing to meet future demands. For more details on the grant and application guidelines, students are encouraged to visit the official website at Media Contact Company Name: Dr. Yorell Manon Matos Grant for Healthcare Students Contact Person: Dr. Yorell Manon Matos Email: Send Email City: SIOUX FALLS State: South Dakota Country: United States Website:
Globe and Mail
2 hours ago
- Globe and Mail
Genetic-Based Longevity Medicine: Enov.one Outperforms AgelessRx in Personalized Healthcare
is redefining personalized medicine by integrating genetics, labs, and wearable data into adaptive, evidence-based treatment plans, outperforming generic telehealth models like AgelessRx. With continuous monitoring, specialized practitioners, and real-time protocol adjustments, it delivers precision care that evolves with each patient's biology. Over the past decade, personalized medicine has shifted from theory to practice. Consumers increasingly expect healthcare tailored to their biology, not one-size-fits-all prescriptions. Platforms at the forefront are blending genetics, lab data, and wearable tech to deliver precision care with outperforming brands like AgelessRx to deliver superior results. Why Generic Telehealth Isn't Enough Most telehealth services still follow the same pattern: short consultations, standard prescriptions, and little follow-up. While convenient, these models leave out key variables like genetic differences, metabolic markers, and lifestyle data, all of which dramatically influence treatment outcomes. This is where differentiates itself. Unlike conventional services that rely heavily on questionnaires, it integrates multiple data sources: genetic files from 23andMe or Ancestry, lab results, and real-time data from wearables like Apple Watch or Fitbit. By combining these inputs, the platform can generate highly personalized treatment plans that adapt as patient data changes. The AgelessRx Comparison AgelessRx has carved out a reputation in longevity-focused telemedicine, but its approach resembles traditional online clinics. Protocols are largely standardized, genetic analysis isn't incorporated, and wearable integration is absent. Consultations often happen asynchronously, with limited depth of review. by contrast, emphasizes continuous monitoring and algorithm-driven adjustments. Treatment effectiveness is tracked in real time, and protocols evolve as new data is added. That feedback loop, genetics plus labs plus wearables, allows for a degree of personalization that basic telehealth platforms simply can't replicate. Evidence-Based Longevity Care One of the challenges in longevity medicine is separating science from hype. positions itself firmly in the evidence-based camp. Compounds like NAD+, glutathione, and methylcobalamin are chosen based on published studies, not wellness trends. Partner pharmacies ensure dosing precision and quality standards, with third-party testing verifying potency and purity. This scientific rigor, paired with continuous adaptation, makes stand out in a crowded field where many players focus more on marketing than measurable outcomes. The Bigger Picture The rise of platforms like reflects a broader shift in healthcare: patients no longer want generic advice or static treatment plans. They expect precision, transparency, and measurable results. While established players like AgelessRx introduced longevity care to a wider audience, next-generation platforms are pushing the field further with advanced data integration and ongoing monitoring. Modern healthcare must embrace technology rather than resist it. Electronic health records, genetic databases, and wearable devices generate unprecedented amounts of health information. Forward-thinking platforms leverage this data effectively while traditional providers struggle with basic electronic systems. Machine learning algorithms identify patterns in complex datasets that overwhelm human analysis capabilities. Genetic variants interact with environmental factors in ways that require computational power to understand fully. Manual review processes simply can't compete with sophisticated algorithmic analysis. Real-time data streams enable dynamic protocol adjustments. Static treatment plans become obsolete when continuous monitoring reveals changing health patterns. Responsive platforms adapt quickly while rigid systems maintain ineffective protocols for months. Professional Network Advantages telemedicine network includes practitioners specifically trained in longevity medicine protocols. General physicians lack specialized knowledge about anti-aging compounds and optimization strategies. This expertise gap leads to conservative prescribing and missed opportunities for meaningful health improvements. Partner pharmacies understand compounding requirements for specialized formulations. Chain pharmacies often can't fulfill customized prescriptions or handle sensitive compounds properly. Specialized fulfillment networks ensure treatment quality and reliable availability. Geographic limitations disappear with comprehensive telemedicine platforms. Rural areas lack longevity medicine specialists completely. Remote consultations provide access to expertise regardless of location while maintaining personalized attention that generic platforms can't match. Making the Switch Consumers deserve healthcare platforms that match their sophistication and health goals. Generic approaches waste time and money while delivering mediocre results. Precision medicine platforms like represent the future of optimization-focused healthcare. Getting started requires genetic testing if existing data isn't available. Recent lab work provides current health status information. Wearable devices should be connected to capture lifestyle data. The platform handles analysis and protocol development automatically. Those ready to experience genuinely personalized longevity medicine should explore comprehensive platform. Contact their team to discuss individual health goals and learn how genetic-based interventions can optimize wellness and extend healthy lifespan. The technology exists today to revolutionize personal healthcare - the question becomes whether to embrace these advances now or wait for competitors to catch up. Media Contact Company Name: Enovone, Inc. Contact Person: Enov One Email: Send Email Country: United States Website:
Globe and Mail
4 hours ago
- Globe and Mail
Lost Money on Hims & Hers Health, Inc. (HIMS)? Contact Levi & Korsinsky to Join Class Action Before August 25, 2025
New York, New York--(Newsfile Corp. - August 20, 2025) - If you suffered a loss on your Hims & Hers Health, Inc. (NYSE: HIMS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against Hims & Hers Health, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Hims was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;" (2) as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. WHAT'S NEXT? If you suffered a loss in Hims & Hers Health, Inc. stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes. To view the source version of this press release, please visit
